Histone Modifying Complexes
MYC-driven Cancer
- MYC proteins are master regulators of cellular programmes
- Aberrations or upregulation of MYC-related pathways occur in the vast majority of cancers
- MYC signalling enable tumour cells to dysregulate microenvironment & evade host immune response
SAGA Complex in MYC-driven Cancers
- MYC members (GCN5) difficult to target with small-molecule inhibitors
- But Acetyltransferase- and Bromo- domains in GCN5 can be targetted
- GCN5 is part of two distinct Histone-modifying complexes, SAGA and ATAC.
- further reading Targeting histone modifying enzymes for cancer therapy [Mustachio et. al.]
Spectronaut
- Spectral Library from RAW files of combined (Control and Treatment) conditions
- Higher mass tolerance
- no default imputation
- default normalization
- PG Quanity export